Loading…
← CockpitCompetitor Analysis › 688137.SS Suzhou Novoprotein Scientific Co., Ltd. Class AOpen in the cockpit ↗

Suzhou Novoprotein Scientific Co., Ltd. Class A688137.SSCompetitor analysis, valuation and peers

China · CNY·Industrials›Miscellaneous Commercial Services

Chinese maker of recombinant proteins, antibodies and reagents used in life-science research.

≈ A China-based life-science reagents supplierMomentum leader 100
Mkt cap
$1.12B
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$156M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-14.9 pp
WACC 10.6%
Hurdle
n/a
no reverse DCF
Next earnings
167 days
4 May 2027
Close · CNYCN¥105.00
1D-7.7%
1W-24.4%
1M-19.4%
3M+64.1%
6M+117.5%
YTD+162.2%
1Y+138.2%
ATR %15.6%
52w lowhigh37.5% off high

What Suzhou Novoprotein Scientific does

Chinese maker of recombinant proteins, antibodies and reagents used in life-science research.

In one line: A China-based life-science reagents supplier.

Products and services

  • Recombinant proteins
  • Antibodies/reagents

Customers

  • Academic labs
  • Biopharma R&D customers

Where it sits in the supply chain

  • Life-science tools
  • Biological reagents
  • Recombinant proteins/antibodies

What could go right

  • China life-science research spending

What could go wrong

  • Competition from global reagent suppliers

Moat: narrow (scale, process know-how). Broad reagent catalog and manufacturing scale versus smaller domestic peers.

Headquarters: Suzhou, China · Employees: 636

Suzhou Novoprotein Scientific at a glance

Size Suzhou Novoprotein Scientific (688137.SS) is a China Industrials company (Miscellaneous Commercial Services) with a market value of $1.12B, the 1934th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥105.00 on 18 Nov 2026.

Performance Over six months the shares gained 117.5%, against -20.9% for the median peer and -20.0% for the China market (cap-weighted) — highest of 21 in its peer set.

Growth Revenue grew 8.1% over the last twelve months (peer median +7.9%); the operating margin is -61.6% (peer median 11.4%).

Valuation It trades at 42.8× enterprise value to sales against a peer median of 2.5× (most expensive of 21).

Capital Return on invested capital runs 14.9 points below its cost of capital (10.6% WACC).

Next results Next results expected around 4 May 2027 (exchange calendar; dates can move).

Relative performance

10020030021 May 202621 Aug 202618 Nov 2026688137.SS 219Peer median 80
Six months, rebased to 100: Suzhou Novoprotein Scientific against the median of its 20 peers (local-currency closes).

Suzhou Novoprotein Scientific financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥159MCN¥146MCN¥126MCN¥153MCN¥262M
Revenue growth—+15%-17%-42%—
Gross profitCN¥126MCN¥81.7MCN¥60.3MCN¥105MCN¥216M
EBITDAn/a-CN¥59.2M-CN¥63.4M-CN¥25.7MCN¥104M
Net income-CN¥96.8M-CN¥77.8M-CN¥54.4MCN¥12.8MCN¥90.7M
Free cash flow-CN¥173M-CN¥61.2M-CN¥15.4MCN¥44.3M-CN¥32.8M
Capital expenditureCN¥164MCN¥78.9MCN¥44.9MCN¥44.9MCN¥36.8M
Total debtCN¥47.8MCN¥55.6MCN¥66.4MCN¥73.3MCN¥83.1M

Quarterly statements and history in the cockpit →

Suzhou Novoprotein Scientific competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%-20%0%WLDN600645688252RHLD06671515CASH603112688112688392BMAGNRO131970SSMCONCORDBIO688800300938688137.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Suzhou Novoprotein Scientific is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%+30%0×20×40×WLDN600645688252600861RHLD0667CASH603112688112688392BMAG131970SSM688522CONCORDBIO300938SIQ688137.SSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Suzhou Novoprotein Scientific is the large dot.

Suzhou Novoprotein Scientific competitors and peer comparison

How Suzhou Novoprotein Scientific compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Suzhou Novoprotein Scientific against its 20 peers (data as of 18 Nov 2026)
Measure688137.SSPeer medianRank in peer set
1-month return-19.4%-8.8%6th lowest of 21
6-month return+117.5%-20.9%highest of 21
Distance from 52-week high-37.5%-41.1%10th highest of 21
Revenue growth (TTM)+8.1%+7.9%11th highest of 21
Operating margin-61.6%11.4%lowest of 21
EV / Sales42.8×2.5×most expensive of 21
ROIC minus cost of capital-14.9 pp+1.6 pp2nd lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Suzhou Novoprotein Scientific 688137.SSChina$1.12B+117%+8%-62%42.8×n/an/a
Willdan WLDNUnited States$1.13B-20%+19%7%1.5×17.2%+11.8%
Vcanbio Cell & Gene Engineering 600645.SSChina$1.11B-29%-6%12%4.1×8.9%+1.9%
Jadard Technology 688252.SSChina$1.14B-22%+6%12%2.5×12.0%+31.3%
FESCO 600861.SSChina$1.10B-15%+4%1%0.0×n/an/a
Resolute Holdings Management RHLDUnited States$1.16B+34%+10%12%4.2×16.6%n/a
China East Education 0667.HKHong Kong$1.09B-21%+16%22%1.1×-7.5%+4.1%
Nittetsu Mining 1515.TJapan$1.17B-3%+18%8%1.0×n/an/a
Prosegur Cash CASH.MCSpain$1.07B+10%-2%11%0.9×-12.1%+5.7%
Shanxi Huaxiang 603112.SSChina$1.19B-33%+9%11%1.8×0.9%+16.2%
Siglent Technologies 688112.SSChina$1.19B-26%+30%24%9.1×27.7%+22.0%
SBT Ultrasonic Technology 688392.SSChina$1.06B-36%+42%17%6.5×n/an/a
Bajaj Mobility BMAG.SWSwitzerland$1.05B+40%-47%-44%1.8×n/an/a
Neurones NRO.PAFrance$1.03B+3%+7%9%0.8×-7.9%+10.3%
DOOSAN TESNA 131970.KSSouth Korea$1.03B-62%+5%10%5.0×n/an/a
Service Stream SSM.AXAustralia$1.03B-9%+1%3%0.7×13.9%+24.0%
Naruida Technology 688522.SSChina$1.01B-32%+20%14%9.4×n/an/a
Concord Biotech CONCORDBIO.NSIndia$1.26B-2%+4%28%9.7×44.4%+11.6%
Suzhou Recodeal Interconnect System 688800.SSChina$1.26B-68%+5%9%2.6×22.7%+38.9%
EMTEK (Shenzhen) 300938.SZChina$1,000M-54%+11%27%7.7×n/an/a
Smartgroup SIQ.AXAustralia$986M-6%+10%37%3.6×-1.3%+8.8%

Questions

Which companies are Suzhou Novoprotein Scientific's closest peers?
The cockpit's peer set: Willdan (WLDN), Vcanbio Cell & Gene Engineering (600645.SS), Jadard Technology (688252.SS), FESCO (600861.SS), Resolute Holdings Management (RHLD), China East Education (0667.HK), Nittetsu Mining (1515.T), Prosegur Cash (CASH.MC).
Is Suzhou Novoprotein Scientific expensive compared with its peers?
On ev / sales it trades at 42.8× against a peer median of 2.5×, most expensive of 21 in its peer set.
How has Suzhou Novoprotein Scientific stock performed?
Over six months to 18 Nov 2026 the shares returned +117.5% against -20.9% for the median peer; over one year +138.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.